Drugs of abuse have a wide range of definitions, ranging from products that enhance performance to psychoactive products. According to the South African Community Epidemiology Network on Drug Use (SACENDU) alcohol remains the dominant substances of abuse in South Africa. Other prominent drugs are cannabis (THC), methaqualone, cocaine, opiates, methamphetamine, amphetamine, over-the-counter (OTC) and prescription medicine.
Methadone Metabolite (EDDP) assay
The CEDIA Methadone Metabolite (EDDP) Assay has revolutionised Methadone screening. Testing for EDDP has largely replaced Methadone as a routine parameter, providing a more effective, accurate and reliable method for the monitoring of compliance in Methadone maintenance programmes.
Testing for EDDP provides more conclusive evidence of Methadone ingestion, decreasing the number of confirmatory analyses.
- Protection of patients with rapid methadone metabolism or on low dose methadone regimes
- Identification of specimens that have been spiked with Methadone
- Renal clearance of EDDP is unaffected by urinary pH resulting in fewer false negatives
Amphetamine / Ecstasy assay
The CEDIA Amphetamines / Ecstasy assay is a single assay designed and developed to measure the most common Designer Drugs, along with Amphetamines and Methamphetamines.
- One assay instead of two assays for detecting Ecstasy compounds (MDMA, MDA, MDEA, MBDB, BDB) plus Amphetamines and Methamphetamines
- Choice of three different cut-offs – 300, 500 and 1.000 ng/ml
Benzodiazepines (high sensitive) assay
This assay offers an excellent recognition of clinically important and abused Benzodiazepines, reducing the risk of false negative results.
- The antibody used in the assay is directed to Nitrazepam to enhance the detection of 7-aminometabolites, for example the recognition of metabolites from the low dosed Benzodiazepines, Flunitrazepam and Clonazepam
- Enhanced detection of glucuronidated metabolites, for example the recognition of glucuronidated metabolites of Oxazepam, Temazepam and Lorazepam
On average, nearly 90% of the commonly administered Benzodiazepines are excreted as glucuronidated metabolites. It is now widely recognised that pre-treatment of samples for Benzodiazepine screening is essential in order to hydrolyse glucuronidated metabolites, so that they can be detected by the antibody in the immunoassay. These positive samples would be missed using conventional assays. Utilising a combination of the CEDIA technology and integrated on-line hydrolysis, the CEDIA Benzodiazepines assay protocol provides a rapid, convenient and superior method for Benzodiazepine screening, setting new standards for sensitivity and performance, without the need for manual pre-treatment.